MIRA Pharmaceuticals, Inc. (MIRA) Balance Sheet
MIRA balance sheet, 2025
December 31, 2025 · U.S. dollars$11.1M assets = $702,068 liabilities + $10.4M equity
Both columns are drawn to the same scale: what MIRA owns equals what it owes plus shareholders’ equity. Hover a block for its value.
MIRA financial health
Descriptive bands, not a rating. Fiscal 2025.
MIRA balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $22,3712020 | $11.1M2025 | +246.0%/yr | |
| Total liabilities | $90,3642020 | $702,0682025 | +50.7%/yr | |
| Shareholders’ equity | −$67,9932020 | $10.4M2025 | — | |
| Cash & short-term investments | $3,4912020 | $6.3M2025 | +348.7%/yr | |
| Total debt | $90,0002020 | $5,0612023 | −61.7%/yr | |
| Net cash (debt) | −$86,5092020 | $4.6M2023 | +$4.7M | |
| Working capital | −$86,8732020 | $10.4M2025 | +$10.4M | |
| Book value per share | −$0.002020 | $0.442025 | — | |
| Debt / equity | 0.132021 | 0.002023 | −0.13 | |
| Shares outstanding | 14.7M2020 | 23.7M2025 | +10.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
MIRA assets
MIRA liabilities and equity
MIRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
MIRA balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $6.3M | $2.8M | $4.6M | $350,978 | $2.8M | $3,491 |
| Cash & equivalents | $6.3M | $2.8M | $4.6M | $350,978 | $2.8M | $3,491 |
| Short-term investments | $4.7M | $0 | — | — | — | — |
| Receivables | $0 | $0 | $11,862 | $0 | $0 | $0 |
| Inventory | $0 | $0 | −$11,862 | $0 | $0 | $0 |
| Other current assets | $4.7M | $54,729 | $255,664 | $143,427 | $100,000 | $0 |
| Total current assets | $11.1M | $2.9M | $4.9M | $494,405 | $2.9M | $3,491 |
| Property, plant & equipment (net) | $0 | $0 | $5,061 | $363,669 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $35,439 | $35,439 | $69,152 | $0 | $445,612 | $18,880 |
| Total assets | $11.1M | $2.9M | $4.9M | $858,074 | $3.4M | $22,371 |
| Liabilities | ||||||
| Accounts payable | $129,203 | $723,349 | $538,564 | $905,554 | $228,406 | — |
| Short-term debt | — | — | $5,061 | $406,964 | $293,062 | $90,000 |
| Deferred revenue | — | — | −$19,533 | — | — | — |
| Total current liabilities | $702,068 | $723,349 | $558,097 | $1.4M | $1.1M | $90,364 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | $0 | $5,061 | $358,169 | $0 | — |
| Other long-term liabilities | $0 | $0 | $0 | $84,267 | $0 | $0 |
| Total liabilities | $702,068 | $723,349 | $558,097 | $1.5M | $1.1M | $90,364 |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $4,194 | $1,656 | $1,478 | $6,657 | $6,337 | $5,887 |
| Retained earnings (deficit) | −$39.6M | −$29.1M | −$21.3M | −$9.3M | −$2.2M | −$67,993 |
| Accumulated other comprehensive income | — | — | — | — | — | −$5,887 |
| Total shareholders' equity | $10.4M | $2.2M | $4.4M | −$596,232 | $2.3M | −$67,993 |
| Key figures | ||||||
| Total debt | — | — | $5,061 | $491,231 | $293,062 | $90,000 |
| Net cash (debt) | — | — | $4.6M | −$140,253 | $2.5M | −$86,509 |
| Working capital | $10.4M | $2.2M | $4.3M | −$875,634 | $1.8M | −$86,873 |
| Tangible book value | $10.4M | $2.2M | $4.4M | −$596,232 | $2.3M | −$67,993 |
| Book value per share | $0.44 | $0.14 | $0.24 | −$0.04 | $0.15 | −$0.00 |
| Shares outstanding | 23.7M | 15.4M | 18.6M | 14.7M | 14.7M | 14.7M |
| Current ratio | 15.75 | 3.99 | 8.70 | 0.36 | 2.66 | 0.04 |
| Quick ratio | 9.04 | 3.92 | 8.27 | 0.26 | 2.57 | 0.04 |
| Debt / equity | — | — | 0.00 | — | 0.13 | — |
| Equity / assets | 93.7% | 75.3% | 88.7% | −69.5% | 67.4% | −303.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $8.1M | $9.4M | $6.3M | $2.6M | $730,475 | $1.2M | $2.8M | $4.1M | $2.8M | $3.5M | $4.6M | $5.9M |
| Cash & equivalents | $3.6M | $4.8M | $6.3M | $2.6M | $730,475 | $1.2M | $2.8M | $4.1M | $2.8M | $3.5M | $4.6M | $5.9M |
| Short-term investments | $4.5M | $4.6M | $4.7M | $4.9M | — | — | $0 | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $35,439 | $35,439 | $0 | $0 | $0 | $0 | $11,862 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $54,286 | $21,748 | $4.7M | $4.9M | $66,965 | $158,614 | $54,729 | $86,572 | $108,622 | $173,474 | $255,664 | $202,817 |
| Total current assets | $8.2M | $9.4M | $11.1M | $7.6M | $832,879 | $1.4M | $2.9M | $4.2M | $2.9M | $3.7M | $4.9M | $6.1M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1,273 | $5,061 | $114,357 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $35,439 | $35,439 | $35,439 | $35,439 | $35,439 | $35,439 | $35,439 | $35,439 | $83,175 | $93,487 | $69,152 | $2.8M |
| Total assets | $8.2M | $9.5M | $11.1M | $7.6M | $868,318 | $1.4M | $2.9M | $4.3M | $3.0M | $3.8M | $4.9M | $9.0M |
| Liabilities | ||||||||||||
| Accounts payable | $40,823 | $34,008 | $129,203 | $83,926 | $298,459 | $100,673 | $723,349 | $692,833 | $782,140 | $636,261 | $538,564 | $510,688 |
| Short-term debt | — | — | — | — | — | — | — | — | — | $1,273 | — | $74,328 |
| Deferred revenue | — | — | — | — | — | — | — | — | — | $1 | — | — |
| Total current liabilities | $40,823 | $114,761 | $702,068 | $83,926 | $298,459 | $106,173 | $723,349 | $692,833 | $796,612 | $652,006 | $558,097 | $868,373 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | — | $0 | $0 | $0 | $1,273 | $5,061 | $108,856 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $34,528 |
| Total liabilities | $40,823 | $114,761 | $702,068 | $83,926 | $298,459 | $106,173 | $723,349 | $692,833 | $796,612 | $652,006 | $558,097 | $902,901 |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $4,202 | $4,202 | $4,194 | $3,951 | $1,739 | $1,682 | $1,656 | $1,627 | $1,478 | $1,478 | — | $1,478 |
| Retained earnings (deficit) | −$41.9M | −$40.7M | −$39.6M | −$33.6M | −$32.5M | −$30.9M | −$29.1M | −$26.7M | −$24.7M | −$23.0M | −$21.3M | −$15.5M |
| Total shareholders' equity | $8.2M | $9.3M | $10.4M | $7.5M | $569,859 | $1.3M | $2.2M | $3.6M | $2.2M | $3.2M | $4.4M | $8.1M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | — | — | — | — | $1,273 | — | $108,856 |
| Net cash (debt) | — | — | — | — | — | — | — | — | — | $3.5M | — | $5.8M |
| Working capital | $8.1M | $9.3M | $10.4M | $7.5M | $534,420 | $1.3M | $2.2M | $3.5M | $2.1M | $3.1M | $4.3M | $5.2M |
| Tangible book value | $8.2M | $9.3M | $10.4M | $7.5M | $569,859 | $1.3M | $2.2M | $3.6M | $2.2M | $3.2M | $4.4M | $8.1M |
| Book value per share | $0.19 | $0.22 | $0.44 | $0.39 | $0.03 | $0.08 | $0.14 | $0.24 | $0.15 | $0.16 | $0.30 | $0.55 |
| Shares outstanding | 42.0M | 41.9M | 23.7M | 19.3M | 17.0M | 16.6M | 15.3M | 15.1M | 14.8M | 19.7M | 14.8M | 14.8M |
| Current ratio | 200.08 | 82.16 | 15.75 | 90.53 | 2.79 | 12.86 | 3.99 | 6.11 | 3.68 | 5.70 | 8.70 | 6.99 |
| Quick ratio | 198.75 | 81.97 | 9.04 | 31.90 | 2.57 | 11.36 | 3.92 | 5.98 | 3.54 | 5.43 | 8.25 | 6.76 |
| Debt / equity | — | — | — | — | — | — | — | — | — | 0.00 | — | 0.01 |
| Equity / assets | 99.5% | 98.8% | 93.7% | 98.9% | 65.6% | 92.4% | 75.3% | 83.8% | 73.6% | 82.9% | 88.7% | 90.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
MIRA financial position
At the end of fiscal 2025 (December 31, 2025), MIRA Pharmaceuticals had total assets of $11.1 million (up 279.5% from a year earlier), total liabilities of $0.7 million and shareholders' equity of $10.4 million. Its current ratio was 15.75. In the latest quarter (ended June 30, 2026) total assets were $8.2 million and equity $8.2 million.
Related: MIRA income statement, MIRA cash flow statement, MIRA key metrics. See the MIRA stock overview for the latest quote and news.
MIRA balance sheet FAQ
What are MIRA Pharmaceuticals's total assets?
MIRA Pharmaceuticals reported total assets of $11.1 million at the end of fiscal 2025 (December 31, 2025), compared with $2.9 million a year earlier.
How much cash does MIRA Pharmaceuticals have?
MIRA Pharmaceuticals held $6.3 million in cash and short-term investments at the end of fiscal 2025.
What is MIRA Pharmaceuticals's book value?
MIRA Pharmaceuticals's shareholders' equity (book value) was $10.4 million at the end of fiscal 2025, or $0.44 per share.
What is MIRA Pharmaceuticals's current ratio?
MIRA Pharmaceuticals had current assets of $11.1 million and current liabilities of $0.7 million, a current ratio of 15.75 (it can cover its short-term obligations).